Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Using biological materials to repair bone defects around teeth

Official title: Evaluation of the Addition of Different Biologicals in the Surgical Treatment of Periodontal Intra-Bony Defects: A Randomised Controlled Clinical Trial.

Run by Universitaire Ziekenhuizen KU Leuven · NCT07292870 · Data updated 2026-11-12

This study will test whether enamel matrix, hyaluronic acid, platelet‑rich fibrin, or a bone graft can help repair intra‑bony defects around teeth in adults with periodontitis who need minimally invasive gum surgery.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment30 (estimated)
SponsorUniversitaire Ziekenhuizen KU Leuven
Academic / other
Drugs / interventionschemotherapy, radiation
Locations1 site (Leuven, Vlaams Brabant)
StatusRecruiting
StartedAugust 8, 2025
Main results expectedDecember 31, 2027
Study endsDecember 31, 2027
Registry record updatedMarch 17, 2026
Trial IDNCT07292870 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older with periodontitis who have completed non‑surgical therapy and have non‑contained (2‑wall) intra‑bony defects of ≥6 mm who are medically fit for minimally invasive periodontal surgery (ASA I–II) are ideal candidates.

Probably not a fit

People under 18, those with medical conditions that would jeopardize safety or protocol compliance, those with prior or concurrent treatments that compromise outcomes, or those without the specified 2‑wall defects are unlikely to benefit from enrollment.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults who meet entry criteria undergo minimally invasive surgical access to clean the intra‑bony defect and are then randomly assigned to receive one of four biomaterial approaches: xenograft (Bio‑Oss® Collagen) plus enamel matrix derivative (Emdogain®), xenograft plus hyaluronic acid (REGENFAST®), xenograft plus L‑PRF (leukocyte and platelet rich fibrin), or L‑PRF alone. The trial uses a non‑inferiority design to test whether hyaluronic acid or L‑PRF achieve at least the same clinical attachment level (CAL) gains as the enamel matrix derivative. Outcomes include changes in CAL and probing pocket depth (PPD) at 6 and 12 months, volumetric soft‑tissue (papilla) preservation by intra‑oral scan, and radiographic measures of defect resolution and bone fill. Procedures are performed at a single academic dental center with standard perioperative care and follow‑up visits at 6 and 12 months.

Why it matters

Potential benefit: If successful, the alternatives could provide equally effective and potentially simpler or more accessible biological options to the current enamel matrix standard for repairing periodontal bone defects.

How similar studies have gone: Enamel matrix derivatives are an established treatment and smaller studies support benefits from platelet concentrates and hyaluronic acid, but direct head‑to‑head non‑inferiority comparisons remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
* At least 18 years of age at the time of signing the Informed Consent Form (ICF)
* American Society of Anesthesiology (ASA) score I or II
* Has already completed the non-surgical periodontal therapy with remaining local pockets of ≥ 6 mm14
* The intra-bony defect should be non-contained (2-wall defect)
* Clinical indication for surgical treatment of the intra-bony defect with minimally invasive approach in conjunction with biologicals

Exclusion Criteria:

* Under the age of 18 years
* Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol
* Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial
* Participation in an interventional Trial with an investigational medicinal product (IMP) or device
* Known or suspected current malignancy
* History of chemotherapy
* History of radiation in the head and neck region
* History of other metabolic bone diseases
* Current or previous use of intravenous and oral bisphosphonates
* Haematological disorders
* Pregnancy / lactation
* Smoking

Where it's running

  • UZLeuven, Campus St. Raphaël, Department Oral Health Sciences, Periodontology
    Leuven, Vlaams Brabant, Belgium
    Recruiting

Study contacts

  • Principal investigator: Ana Castro, Professor — UZLeuven, department of Oral Health Sciences, Periodontology
  • Study coordinator: Ana B Castro Sarda, Professor
  • Email: ana.castro@uzleuven.be
  • Phone: +32 16 332816

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.